Literature DB >> 18416977

The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis.

Richard J Harvey1, Jeeves Kanagalingam, Valerie J Lund.   

Abstract

BACKGROUND: A variety of modalities are available for the control of recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT). Laser ablation, in particular potassium-titanyl-phosphate (KTP), has gained popularity as it coagulates the telangiectasia with minimal peripheral tissue injury. Septodermoplasty (SDP) also can be performed in the day surgery setting. Telangiectasia recurred, necessitating repeated treatments. The frequency and interval between procedures is not well documented. The purpose of this study was to describe the frequency of surgical interventions for HHT patients and the impact of SDP.
METHODS: A retrospective review was undertaken of procedures performed in a tertiary hospital unit during a 60-month period for HHT. The incidence of KTP laser and SDP, days between treatments, total number of interventions and perioperative hemoglobin (Hb) were audited. Patient groups were identified as definite or possible HHT according to the Curaçao criteria. All suffered from epistaxis sufficient to seek medical treatment.
RESULTS: Three hundred one procedures were performed on 131 patients during the study period. In total, 33 SDPs and 268 KTP laser treatments were performed; 78.3% of patients required three or less procedures. The mean time interval between treatments was 473 (+/-515 days) days. The rate of KTP after an SDP decreased from 1.83 (+/-1.99) to 0.78 (+/-0.85; p=0.012). Hb level was not associated with treatments required.
CONCLUSION: Surgical interventions with laser and SDP in HHT are always time limited as recurrence of telangiectasia is inevitable. This study discusses the expectations of therapy, mainly frequency and duration of effect, along with the impact of SDP. The outcomes assist in better management of patient expectations.

Entities:  

Mesh:

Year:  2008        PMID: 18416977     DOI: 10.2500/ajr.2008.22.3145

Source DB:  PubMed          Journal:  Am J Rhinol        ISSN: 1050-6586


  16 in total

Review 1.  Diagnosis and Treatment of Hereditary Hemorrhagic Telangiectasia.

Authors:  Cameron Grigg; Daniel Anderson; James Earnshaw
Journal:  Ochsner J       Date:  2017

2.  Randomized controlled trial comparing Nd:YAG laser photocoagulation and bipolar electrocautery in the management of epistaxis.

Authors:  Jing Zhang; Luhong Cao; Chunsheng Wei
Journal:  Lasers Med Sci       Date:  2017-07-13       Impact factor: 3.161

3.  Treatment of severe refractory epistaxis in hereditary hemorrhagic telangiectasia using a two-flap nasal closure method.

Authors:  Benjamin H Timmins; Benjamin N Hunter; Kevin F Wilson; P Daniel Ward
Journal:  Int Forum Allergy Rhinol       Date:  2016-01-11       Impact factor: 3.858

Review 4.  Laser-Assisted Control of Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.

Authors:  Arash Abiri; Khodayar Goshtasbi; Marlon Maducdoc; Ronald Sahyouni; Marilene B Wang; Edward C Kuan
Journal:  Lasers Surg Med       Date:  2019-08-22       Impact factor: 4.025

5.  Patient-recorded benefit from nasal closure in a Danish cohort of patients with hereditary haemorrhagic telangiectasia.

Authors:  Jonas Hjelm Andersen; Anette Drøhse Kjeldsen
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-12-16       Impact factor: 2.503

6.  A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.

Authors:  C Rohrmeier; H G Sachs; T S Kuehnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-31       Impact factor: 2.503

7.  Diode laser in the treatment of epistaxis in patients with hereditary haemorrhagic telangiectasia.

Authors:  M L Fiorella; L Lillo; R Fiorella
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-06       Impact factor: 2.124

8.  A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab.

Authors:  Ahmad Amanzada; Gwen-Jana Töppler; Silke Cameron; Harald Schwörer; Giuliano Ramadori
Journal:  Case Rep Oncol       Date:  2010-12-11

9.  Nasal surgery in patients with systemic disorders.

Authors:  Florian Sachse; Wolfgang Stoll
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2011-04-27

10.  Technique modifications for septodermoplasty: an illustrative case.

Authors:  Mark Bastianelli; Shaun J Kilty
Journal:  J Otolaryngol Head Neck Surg       Date:  2015-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.